Loading
A Colombian study of a rapid test that reads overall DNA methylation in blood, urine or saliva using gold nanoparticles.
METHYLSCAPE-CO (NCT07741435) is an observational study sponsored by Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo. It evaluates the sensitivity and specificity of Methylscape, which uses the different binding of methylated and unmethylated DNA to gold nanoparticles to detect a cancer signal and predict its origin.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 3,250 participants, a start on 5 June 2025 and primary completion expected on 4 June 2027.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/